The National Cancer Institute (NCI) announces a funding opportunity for Specialized Programs of Research Excellence (SPOREs) in Human Cancers spanning 2024 to 2026. This initiative invites applications for P50 Research Center Grants aimed at innovative translational research to improve cancer prevention, early detection, diagnosis, and treatment. The research should be focused on organ-specific cancers or related groups, and clinical trials are required. Key dates include an open application period beginning on December 25, 2023, with specific deadlines for submissions in January, May, September, and January 2026. Funds are available for approximately six to ten SPORE awards per year, with a maximum of $1.4 million in direct costs annually for projects meeting certain criteria. The SPORE program emphasizes collaboration, the establishment of research infrastructure, and engagement in cross-cutting themes such as health disparities. Applicants must demonstrate an ability to achieve translational human endpoints within five years and include a plan to enhance diversity. Each application must integrate core components: Administrative, Shared Resources, Developmental Research, and Career Enhancement programs. The document outlines detailed application instructions to ensure compliance and encourages engagement with NCI staff for guidance prior to submission. This call for proposals highlights the government's ongoing commitment to advancing cancer research and improving treatment outcomes through targeted funding initiatives.